CN1453295A - Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition - Google Patents
Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition Download PDFInfo
- Publication number
- CN1453295A CN1453295A CN 03127034 CN03127034A CN1453295A CN 1453295 A CN1453295 A CN 1453295A CN 03127034 CN03127034 CN 03127034 CN 03127034 A CN03127034 A CN 03127034A CN 1453295 A CN1453295 A CN 1453295A
- Authority
- CN
- China
- Prior art keywords
- medusae
- polysaccharide
- hericium caput
- caput
- hericium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 45
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 45
- 150000004676 glycans Chemical class 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims description 9
- 241000289669 Erinaceus europaeus Species 0.000 title abstract 4
- 241000233866 Fungi Species 0.000 title abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 23
- 238000001556 precipitation Methods 0.000 claims abstract description 23
- 208000007882 Gastritis Diseases 0.000 claims abstract description 13
- 230000001175 peptic effect Effects 0.000 claims abstract description 9
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 8
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 8
- 208000025865 Ulcer Diseases 0.000 claims abstract description 7
- 230000002183 duodenal effect Effects 0.000 claims abstract description 7
- 231100000397 ulcer Toxicity 0.000 claims abstract description 7
- 102000004190 Enzymes Human genes 0.000 claims abstract description 5
- 108090000790 Enzymes Proteins 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000006228 supernatant Substances 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 3
- 241000123222 Hericium Species 0.000 claims description 59
- 206010072284 Varicose veins of abdominal wall Diseases 0.000 claims description 59
- 239000004615 ingredient Substances 0.000 claims description 35
- 101100178313 Aedes aegypti HP-I gene Proteins 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229960004756 ethanol Drugs 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 230000036592 analgesia Effects 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- -1 through dialysis Substances 0.000 claims description 3
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 2
- 206010020601 Hyperchlorhydria Diseases 0.000 claims description 2
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 2
- 230000003544 deproteinization Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract 2
- 239000003708 ampul Substances 0.000 abstract 1
- 238000005119 centrifugation Methods 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 208000018556 stomach disease Diseases 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 description 46
- 241001465754 Metazoa Species 0.000 description 21
- 208000004300 Atrophic Gastritis Diseases 0.000 description 10
- 208000036495 Gastritis atrophic Diseases 0.000 description 10
- 210000004051 gastric juice Anatomy 0.000 description 9
- 238000010189 synthetic method Methods 0.000 description 8
- 230000000007 visual effect Effects 0.000 description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 210000001156 gastric mucosa Anatomy 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 4
- 230000000762 glandular Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 102100021022 Gastrin Human genes 0.000 description 3
- 108010052343 Gastrins Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229940071462 oralone Drugs 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 108700002722 mouse granuloma Proteins 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Spinulate hedgehog fungus with sporophore used as material is processed through water decoction for 1-3 times, filtering with filtrate being merged, concentration, addition of enzyme, regulating of temperature and pH value, elimination of protein, straining, alcohol precipitation, filtering to collect precipitate, water dissolving, centrifugation to eliminate dregs, and alcohol precipitation of supernatant to collect spinulate hedgehog fungus polysaccharide. Medicine with spinulate hedgehog fungus polysaccharide as main medicinal component is provided and the medicine may be used in treating chronic atrophic gastritis, superficial gastritis, peptic gastric ulcer, duodenal ampulla ulcer and other gastric diseases and has pain relieving and antiinflammation functions.
Description
Technical field:
The present invention discloses a kind of Hericium caput-medusae polysaccharide medicinal component, its preparation method is provided simultaneously and is the pharmaceutical composition of active ingredient with this compound, belongs to effective components of Chinese medicinal and extracts and applied technical field.
Background technology:
Hericium caput-medusae Hericium Caput-medusae of the present invention (Bull.ex Fr) Pers is that " stomach is happy new " is same bacterial strain with the medicine for the treatment of stomach ulcer, chronic atrophic gastritis." stomach happy new " is through submerged fermentation, fermented liquid is made after concentrated and formed then with Small acupuncture Hericium erinaceus (Bull. Ex Fr.) Pers..Because un-extracted contains multiple substratum composition, the active substance composition is unclear, and the quality standard controllability of medicine is not strong, and also contains a large amount of sugars in the medicine, brings inconvenience for diabetics's application, and its treatment is used and has been subjected to very big restriction.
Summary of the invention:
The invention provides a kind of Hericium caput-medusae polysaccharide medicinal component (below subtract claim HP).
Extracting effective components HP I and HP II from HP have been the present invention further provides.
The present invention also provides the preparation method who extracts above-mentioned substance from Hericium caput-medusae, is applicable to suitability for industrialized production.
The present invention further provides with Hericium caput-medusae polysaccharide component and be main medicine or be used for treatment of diseases such as chronic atrophic gastritis, superficial gastritis, peptic gastric ulcer, duodenal bulbar ulcer, hypoimmunity, tumour and analgesia, anti-inflammatory action etc. with the other medicines prescription.
The structural formula of Hericium caput-medusae polysaccharide effective ingredient is as follows: HP I molecular formula:
Wherein, A:-
1Fuc
4-; B:-(
1Glc
3-)
2-; C:-(
1Glc
6-)
3-.HP II molecular formula:
Wherein, A:-(
1Glc
3-)
2-; B:-
1Gal
6-.
The Hericium caput-medusae polysaccharide obtains by following extracting method:
Method 1
With the Hericium caput-medusae sporophore is raw material, uses decocting 1～3 time, and each time is 1～3 hour, filters, and merging filtrate concentrates, add enzyme 0～3g and carry out enzyme digestion reaction, and 45～60 ℃ of temperature adjustments, pH value 5～7 is except that Deproteinization; Add ethanol after the smart filter and carry out alcohol precipitation, ultimate density is 70%, filters collecting precipitation, and is water-soluble, centrifugal slagging-off, and getting supernatant liquor alcohol, to be sink to determining alcohol be 70%, alcohol precipitation 2-3 time, the Hericium caput-medusae polysaccharide (HP) of collecting precipitation.
Method 2
With the Hericium caput-medusae is raw material, and with 20% alcohol reflux 3 times, each time is 3 hours, united extraction liquid, it is 80% to containing the alcohol amount that concentrating under reduced pressure, concentrated solution add ethanol, alcohol precipitation 2-3 time, left standstill 24 hours, suction filtration, throw out washs in right amount with dehydrated alcohol, drying, be ground into fine powder, get Hericium caput-medusae polysaccharide (HP).
Method 1 or the water-soluble back of method 2 gained polysaccharide (HP) are gone up DEAE-SepharoseCL-6B column purification, 0.1mol.L
-1+ 0.15mol.L
-1The conventional wash-out of NaCl, through dialysis, concentrate, freeze-drying gets HP I.Use 0.1mol.L again
-1+ 4.5mol.L
-1The NaCl gradient elution, through dialysis, concentrate, freeze-drying gets HP II.
Press practice of pharmacy, Hericium caput-medusae polysaccharide of the present invention can be prepared into the medicine of various clinical pharmaceutical dosage form as treatment of diseases such as chronic atrophic gastritis, superficial gastritis, peptic gastric ulcer, duodenal bulbar ulcer, hypoimmunity, tumour and antalgic and inflammation relieving, said medicament is a said formulation on any pharmaceutics.Wherein, oral preparations is selected from any in tablet, capsule, pill, granule, suspensoid, the dropping pill formulation.
Medicine of the present invention preferably contains the Hericium caput-medusae polysaccharide of 1%-99% and the vehicle of 99%-1% (medicine that comprises other compatibility), preferably contain the Hericium caput-medusae polysaccharide of 30%-80% and the pharmaceutical excipient of 70%-20% (comprising the medicine that other compatibility is used), preferably contain the Hericium caput-medusae polysaccharide of 60%-70% and the vehicle of 40%-30% (comprising the medicine that other compatibility is used).
Auxiliary material in the medicine of the present invention is meant conventional vehicle, as solvent, disintegrating agent, correctives, sanitas, tinting material, tackiness agent etc.The medicine that other compatibility in the medicine of the present invention is used, the Hericium caput-medusae polysaccharide that refers to effective dose is certain medicine material, again compatibility other can allow the Chinese medicine or the pharmaceutical chemicals that share.
Following pharmacological evaluation has confirmed that Hericium caput-medusae polysaccharide medicine preparation has pharmacologically actives such as disease such as treatment chronic atrophic gastritis, superficial gastritis, peptic gastric ulcer, duodenal bulbar ulcer and analgesia:
The chronic atrophic gastritis that table 1 Hericium caput-medusae sporophore efficient part and effective ingredient cause ammoniacal liquor
The influence of rat gastric juice composition (X ± S)
Model group and normal control group be △ P＜0.05 relatively; △ △ △ P＜0.001, administration group and model group be * P＜0.05 relatively; * P＜0.01.
| The free mucus amount serum stomach of group dosage number of animals stomach free acidity gastric juice peptic activity of stomach gastric juice must plain (mg/kg) (mmol/l) (μ) mg-A Xinlan (pg/ml) |
| Normal control-8 66.25 ± happy new 3.85g/kg 10 65.0 ± the 21.21* 82.75 of 21.99 133.78 ± 85.45 0.506 ± 0.11 51.39 ± 14.07 models contrast-10 43.0 ± 23.59 △, 45.38 ± 14.46 △ △ △, 0.554 ± 0.19 68.67 ± 20.62 △ stomach ± 68.43 0.479 ± 0.16 37.25 ± 6.97** HP I effective ingredients, 35.0 10 54.0 ± 17.13 72 ± 20.71** 0.536 ± 0.09 42.16 ± 9.28* * HP active component, 140.0 10 80.0 ± 50.99*, 108.58 ± 64.05* 0.558 ± 0.08 46.57 ± 10.88 * HP active component, 70.0 10 63.0 ± 22.14 98.08 ± 54.09* 0.495 ± 0.06 56.86 ± 15.87 HP active components, 35.0 9 74.4 ± 35.09*, 94.55 ± 32.93** 0.546 ± 0.09 60.54 ± 13.81 |
By table 1 interpretation of result, drink ammoniacal liquor and can cause the rat chronic atrophic gastritis in 90 days, moulding group and normal control group are relatively, free acidity reduces (P＜0.05) in the gastric juice, and each administration group drug treatment all has improvement in various degree after 30 days, make the active increase of free acidity and gastric pepsin digestion, serum gastrin content reduces.
The chronic atrophic gastritis that table 2 Hericium caput-medusae sporophore efficient part and effective ingredient cause ammoniacal liquor
The influence of cAMP and cGMP content in the rat plasma (X ± S)
Model group and normal group be △ P＜0.05 relatively; Administration group and model group be * P＜0.05 relatively.The result shows by table 2, and no matter the Hericium caput-medusae sporophore is the content that effective ingredient or efficient part all can reduce cGMP, the content of rising cAMP (P＜0.05).
| Group | Dosage | Number of animals | ????cAMP | ???cGMP(PM/ml) |
| The happy new HP I effective ingredient HP active component HP active component HP active component of Normal group model control group stomach | ??- ??- ??3.85g/kg ??35mg/kg ??140mg/kg ??70mg/kg ??35mg/kg | ????8 ????10 ????9 ????10 ????10 ????10 ????10 | ????0.50±0.19 ????0.31±0.14 ????0.49±0.27 ????0.44±0.11* ????0.43±0.15* ????0.49±0.26 ????0.39±0.24 | ???0.16±0.045 ???0.24±0.075△ ??????0.15±0.044* ???0.17±0.075* ???0.17±0.064* ???0.17±0.062* ???0.20±0.075 |
The chronic atrophic gastritis that table 3 Hericium caput-medusae sporophore efficient part and effective ingredient cause ammoniacal liquor
The influence of gastric mucosa of rat flesh layer and lamina muscularis mucosae gastris thickness (X ± S μ m)
Model group and control group be △ P＜0.05 relatively; △ △ △ P＜0.001; Administration group and model group be * P＜0.05 relatively; * P＜0.01; * * P＜0.001.
| Group dosage number of animals stomach hole stomach hole body of stomach gastric body mucosa layer thickness lamina muscularis mucosae gastris thickness mucous layer thickness muscular layer of mucosa thickness |
| The happy new 3.85g/kg 8 4.06 ± 0.48* 0.34 of normal control group-8 5.08 ± 0.55 0.39 ± 0.051 5.55 ± 0.58 0.43 ± 0.084 model control group-10 3.68 ± 0.33 △ △ △, 0.34 ± 0.078 3.70 ± 0.39 △ △ △, 0.36 ± 0.055 △ stomach ± 0.09 4.6 ± 0.35***, 0.33 ± 0.046 HP I effective ingredient 35mg/kg, 8 4.66 ± 0.45**, 0.34 ± 0.06 5.24 ± 0.31***, 0.35 ± 0.038 HP active component 140mg/kg, 8 4.89 ± 0.66***, 0.34 ± 0.042 5.46 ± 0.44***, 0.34 ± 0.058 HP active component 70mg/kg, 8 4.33 ± 0.41**, 0.31 ± 0.032 4.99 ± 0.32***, 0.34 ± 0.042 HP active component 35mg/kg, 8 4.27 ± 0.39***, 0.33 ± 0.038 4.81 ± 0.19*** 0.32 ± 0.037 |
The result shows by table 3, and each group of Hericium caput-medusae sporophore effective ingredient and efficient part all can obviously suppress the atrophy attenuation of stomach hole and gastric body mucosa, with model control group the difference of highly significant is arranged relatively.
Table 4 Hericium caput-medusae sporophore efficient part and effective ingredient are to experimental atrophic gastritis
Pathological examination results (X ± S)
| Group dosage number of animals check point stomach hole body of stomach hole body intersection glandular stomach gastric gland intersection 0+++ +++0+++ +++0+++ +++0+++ +++ |
| The happy new 3.85g/kg 8 16 16 00 19 11 2034102420 HP I effective ingredient 35mg/kg 8 13 14 50 17 14 1025103410 HP active component 140mg/kg 8 18 11 30 17 14 1015202510 HP active component 70mg/kg 8 17 12 30 11 17 4024202330 HP active component 35mg/kg 8 14 14 40 15 13 4023301430 of normal control group-8 28 400 31 10080006200 model group-1,010 22 803 23 1408202530 stomaches |
Annotate: 4 visuals field of every animal (stomach hole, body of stomach) survey, promptly 8 animals are observed 32 visuals field, 10 animals are observed 40 visuals field as the last result who judges the gastritis degree, and all the other two positions (hole body intersection and glandular stomach, gastric gland intersection) every animal is observed a visual field.
Table 4 result is provable because of each administration group of chronic atrophic gastritis of taking the ammoniacal liquor initiation all can make inflammation alleviate, and Hp quantity obviously reduces than model group, shows that this polysaccharide has the obvious treatment effect to experimental chronic gastritis.
Table 5 Hericium caput-medusae sporophore efficient part and effective ingredient to ammoniacal liquor cause chronic
The influence of atrophic gastritis Hp quantity (X ± S)
| Group | Dosage | Number of animals | Hp number (individual) under the high power field |
| The happy new group HP I effective ingredient HP active component HP active component HP active component of control group model group stomach | ?- ?- ?3.85g/kg ?35mg/kg ?140mg/kg ?70mg/kg ?35mg/kg | ????8 ????10 ????10 ????10 ????10 ????10 ????10 | ??????1.80±0.92 ??????16.6±4.79△△△ ????????????8.3±2.45*** ??????6.2±2.11*** ??????6.3±1.56*** ??????8.1±2.13*** ??????9.9±1.9** |
Model group and control group be △ △ △ P＜0.001 relatively
Administration group and model group be * * P＜0.01 relatively; * * P＜0.001
Table 5 result is provable because of each administration group of chronic atrophic gastritis of taking the ammoniacal liquor initiation all can make inflammation alleviate, and Hp quantity obviously reduces than model group, shows that this polysaccharide has the obvious treatment effect to experimental chronic gastritis.
The atrophic that table 6 Hericium caput-medusae sporophore efficient part and effective ingredient cause synthetic method
The influence of gastritis rat gastric juice composition (X ± S)
| The free mucus amount serum stomach of group dosage number of animals stomach free acidity gastric juice peptic activity of stomach gastric juice must plain (mg/kg) (mmol/l) (μ) mg-A Xinlan (pg/ml) |
| Normal control-10 114.0 ± 23.1 122.9 ± 47.3 0.42 ± 0.18 72.13 ± 12.81 models contrast-10 57.0 ± 19.2 △ △, 87.7 ± 20.84 △ 0.45 ± happy new 3.85g/kg 10 70.5 of 0.16 96.03 ± 12.76 △ △ stomach ± 19.1 121.5 ± 39.1* 0.49 ± 0.17 66.79 ± 19.16** HP I effective ingredient, 35.0 10 73.0 ± 19.0 136.5 ± 80.1 0.46 ± 0.11 88.35 ± 26.12 HP active components, 140.0 10 79.0 ± 21.6*, 114.2 ± 30.9* 0.48 ± 0.13 82.84 ± 37.63 HP active component, 70.0 10 84.5 ± 33.3* 101.2 ± 23.1 0.51 ± 0.19 72.97 ± 20.86* HP active component, 35.0 10 71.0 ± 32.6 114.0 ± 29.5*, 0.41 ± 0.16 78.73 ± 18.09** |
Model group and normal control group be △ P＜0.05 relatively; △ △ P＜0.01
Administration group and model group be * P＜0.05 relatively; * P＜0.01
Table 6 is the result show, the atrophic gastritis model that the synthetic method that adopts active immunity and bile and hot water to irritate stomach causes is set up, rat gastric juice free acid reduces after the modeling, pepsin activity weakens, serum gastrin content obviously raises (P＜0.01), and administration is after one month, and each administration group all has therapeutic action in various degree, hydrochloric acid in gastric juice and pepsin activity are strengthened and serum gastrin content reduces (P＜0.05, P＜0.01) than model group.
The atrophic gastritis that table 7 Hericium caput-medusae sporophore efficient part and effective ingredient cause synthetic method
The influence of cAMP and cGMP content in the rat plasma (X ± S)
| Group | Dosage | Number of animals | ?????cAMP | ????cGMP(PM/ml) |
| The happy new group HP I effective ingredient HP active component HP active component HP active component of Normal group model control group stomach | ?- ?- ?3.85g/kg ?35mg/kg ?140mg/kg ?70mg/kg ?35mg/kg | ????10 ????10 ????10 ????10 ????10 ????10 ????10 | ?????0.56±0.40 ?????0.32±0.20 ?????0.41±0.26 ?????0.24±0.15 ?????0.69±0.26** ?????0.56±0.26* ?????0.50±0.32 | ????0.26±0.31 ????0.26±0.14 ????0.18±0.08 ????0.16±0.06 ????0.16±0.08 ????0.19±0.09 ????0.24±0.13 |
Administration group and model group be * P＜0.05 relatively; * P＜0.01
By table 7 result as seen, the normal control group plasma cAMP of the model group trend that significantly decreases, and it is little to the cGMP influence, each administration group (except that the effective ingredient group) plasma cAMP all raises than model control group, especially Hericium caput-medusae sporophore efficient part height, middle dosage group obviously make plasma cAMP content rising (P＜0.01, P＜0.05).
The atrophic gastritis that table 8 Hericium caput-medusae sporophore efficient part and effective ingredient cause synthetic method
The influence of gastric mucosa of rat layer and lamina muscularis mucosae gastris thickness (X ± S μ m)
| Group dosage number of animals stomach hole stomach hole body of stomach gastric body mucosa layer thickness lamina muscularis mucosae gastris thickness mucous layer thickness muscular layer of mucosa thickness |
| Happy new group 3.85g/kg 8 5.04 ± 0.39** 0.27 ± 0.046* 5.31 ± 0.33** 0.28 ± 0.038 HP I effective ingredient 35mg/kg 8 5.35 ± 0.57** 0.31 ± 0.049** 5.02 ± 0.49* 0.31 ± 0.068* HP active component 140mg/kg 8 5.36 ± 0.41** 0.329 ± 0.0412 5.77 ± 0.36*** 0.28 ± 0.038* HP active component 70mg/kg 8 5.38 ± 0.57** 0.24 ± 0.049 5.35 ± 0.41** 0.27 ± 0.059 HP active component 35mg/kg 8 5.23 ± 0.36** 0.23 ± 0.046 5.53 ± 0.35** 0.25 ± 0.053 of normal control group-8 5.28 ± 0.38 0.34 ± 0.074 5.5 ± 0.51 0.38 ± 0.093 model control group-10 4.17 ± 0.38 △ △, 0.22 ± 0.035 △ △, 4.35 ± 0.53 △ △, 0.24 ± 0.046 △ △ stomach |
Model group and control group be △ △＜0.01 relatively; Administration group and model group be * P＜0.05 relatively; * P＜0.01; * * P＜0.001
The result shows by table 8, and each group of Hericium caput-medusae sporophore effective ingredient and efficient part all obviously suppresses the atrophy attenuation of stomach hole and gastric body mucosa, with model control group the difference of highly significant is arranged relatively.
The pathology of the atrophic gastritis rat that table 9 Hericium caput-medusae sporophore efficient part and effective ingredient cause synthetic method
Check result (X ± S)
| Group dosage number of animals inspection area stomach hole body of stomach hole body intersection glandular stomach gastric gland intersection 0+++ +++0+++ +++0+++ +++0+++ +++ |
| The happy new group 3.85g/kg 8 23 900 24 62062005300 HP I effective ingredient 35mg/kg 8 21 11 00 16 16 0053004400 HP active component 140mg/kg 8 21 11 00 14 15 3044004310 HP active component 70mg/kg 8 22 10 00 27 50053003320 HP active component 35mg/kg 8 17 13 20 11 18 3032214400 of normal control group-8 29 300 29 30080006200 model group-10 4 30 606 30 4006400550 stomach |
Annotate: every animal stomach hole and body of stomach are observed 4 visuals field, promptly 8 animals are observed 32 visuals field altogether, 10 animals are then observed 40 visuals field as the last result who judges the gastritis degree, and all the other two positions (hole body intersection and glandular stomach, gastric gland intersection) every animal is observed a visual field.
Each administration group of the atrophic gastritis that the provable synthetic method of table 9 result causes all can make inflammation alleviate, and Hp quantity obviously reduces than model group, shows that this polysaccharide has the obvious treatment effect to atrophic gastritis.
Chronic the withering that table 10 Hericium caput-medusae sporophore efficient part and effective ingredient cause synthetic method
The influence of contracting property gastritis Hp quantity (X ± S)
| Group | Dosage | Number of animals | Hp number (individual) under the high power field |
| The happy new group HP I effective ingredient HP active component HP active component HP active component of control group model group stomach | ??- ??- ??3.85g/kg ??35mg/kg ??140mg/kg ??70mg/kg ??35mg/kg | ????10 ????10 ????10 ????10 ????10 ????10 ????10 | ????1.70±1.25 ????19±7.35△△△ ????????6.2±3.01*** ????4.6±1.17*** ????7.4±2.67** ????11.0±2.05** ????11.4±4.12* |
Model group and control group be △ △ △ P＜0.001 relatively; Administration group and model group be * P＜0.05 relatively; * P＜0.01; * * P＜0.001.
Each administration group of the atrophic gastritis that the provable synthetic method of table 10 result causes all can make inflammation alleviate, and Hp quantity obviously reduces than model group, shows that this polysaccharide has the obvious treatment effect to atrophic gastritis.
Table 11 Hericium caput-medusae sporophore efficient part and effective ingredient push away the full stomach and intestine of mouse
Advance the influence (X ± S) of function
| Group | Dosage | Number of animals | Full stomach and intestine advance percentage % |
| The happy new HP I effective ingredient HP efficient part HP efficient part HP efficient part of control group stomach | ?- ?4.85g/kg ?50mg/kg ?200mg/kg ?100mg/kg ?50mg/kg | ????10 ????10 ????10 ????10 ????10 ????10 | ??????23.73±6.36 ??????47.07±20.39** ??????50.29±20.78** ??????58.95±23.033*** ??????48.06±19.76** ??????49.11±10.99*** |
Compare * * P＜0.01 with control group; * * P＜0.001
Table 11 result as seen, each administration group all strengthens the propulsion functions (P＜0.01, P＜0.001) of mouse stomach and intestine very significantly.
The analgesic activity of table 12 Hericium caput-medusae sporophore efficient part and effective ingredient (X ± S)
| Group | Dosage | Number of animals | Turn round body number of times (inferior) | Inhibiting rate % |
| The happy new HP I effective ingredient HP efficient part HP efficient part HP efficient part of control group stomach | ??- ??4.85g/kg ??50mg/kg ??200mg/kg ??100mg/kg ??50mg/kg | ????10 ????10 ????10 ????10 ????10 ????10 | ?????31.8±5.55 ?????26.2±7.69 ?????25.3±8.63* ?????22.0±9.51* ?????22.8±6.34** ?????26.6±7.21 | ????17.6 ????20.4 ????30.8 ????28.3 ????16.4 |
Compare * P＜0.05 with control group; * P＜0.01
By table 12 as seen, Hericium caput-medusae sporophore efficient part and effective ingredient have the obvious suppression Glacial acetic acid to cause the mouse writhing reaction.
Table 13 Hericium caput-medusae sporophore efficient part and effective ingredient are right
The influence of mouse granuloma induced by implantation of cotton pellets (X ± S)
| Group rate % | Dosage | Number of animals | Granuloma induced by implantation of cotton pellets net weight (mg) | Swelling suppresses |
| The happy new HP I effective ingredient HP efficient part HP efficient part HP efficient part of control group stomach | ??-- ??4.85g/kg ??50mg/kg ??200mg/kg ??100mg/kg ??50mg/kg | ????10 ????10 ????10 ????10 ????10 ????10 | ?????66.2±14.49 ?????54.9±6.98* ?????57.8±8.70 ?????49.8±8.46** ?????54.5±15.67 ?????56.1±10.48 | ?????17.1 ?????12.7 ?????24.8 ?????17.7 ?????15.2 |
Compare * P＜0.05 with control group; * P＜0.01
Table 13 is the result show, stomach is found pleasure in new and Hericium caput-medusae fruitbody polysaccharide 200mg/kg organizes the hyperplasia that obvious suppression mouse granuloma induced by implantation of cotton pellets is all arranged, and other administration group also has the outgrowth trend of inhibition.
Positively effect of the present invention is: medicinal ingredients is evident in efficacy, have no side effect, taking dose is little, can be used for treating diseases such as stomachache that chronic atrophic gastritis, superficial gastritis, peptic gastric ulcer and duodenal bulbar ulcer or other reason cause, hyperchlorhydria, and have analgesia, anti-inflammatory action.
Embodiment:
Embodiment 1
Take by weighing Hericium caput-medusae sporophore 1Kg, add water 20Kg, 95 ℃ are extracted 3 times repeatedly, each 1 hour.United extraction liquid filters, and reduced vacuum concentrates, and heat is surveyed proportion 1.04, smart filter.Add the edible ethanol alcohol precipitation, ultimate density reaches 70%.Filter, collecting precipitation, water-soluble.Centrifugal slagging-off is got supernatant alcohol precipitation (determining alcohol 70%) 2-3 time, collecting precipitation-polysaccharide (HP) 70g.
Embodiment 2
Take by weighing Hericium caput-medusae mycelium 1Kg, add water 20Kg, 98 ℃ are extracted each 1 hour 3 times.United extraction liquid filters, and reduced vacuum concentrates, and heat is surveyed proportion 1.04, smart filter.Add the edible ethanol alcohol precipitation, ultimate density reaches 80%.Filter, collecting precipitation, water-soluble.Centrifugal slagging-off is got supernatant alcohol precipitation (determining alcohol 80%) 2-3 time, collecting precipitation-polysaccharide (HP) 50g.
Embodiment 3
Take by weighing Hericium caput-medusae sporophore 1Kg, add water 20Kg, 96 ℃ are extracted 3 times repeatedly, each 1 hour.United extraction liquid filters, and reduced vacuum concentrates, and heat is surveyed proportion 1.06, smart filter.Add enzyme 2g, temperature adjustment 35-60 ℃, pH value 5-7, hydrolysis removes albumen.Smart filter adds the edible ethanol alcohol precipitation, and ultimate density reaches 60%.Filter, collecting precipitation, water-soluble, alcohol precipitation 2-3 time repeatedly, collecting precipitation-polysaccharide (HP) 70g.
Embodiment 4
Take by weighing Hericium caput-medusae mycelium 1Kg, add water 20Kg, 98 ℃ are extracted 3 times repeatedly, each 1 hour.United extraction liquid filters, and reduced vacuum concentrates, and heat is surveyed proportion 1.02, smart filter.Add enzyme 3g, temperature adjustment 35-55 ℃, pH value 3-5, hydrolysis removes albumen, smart filter.Add the edible ethanol alcohol precipitation, ultimate density reaches 70%.Filter, collecting precipitation, water-soluble, alcohol precipitation 2-3 time repeatedly, collecting precipitation-polysaccharide (HP) 50g.
Embodiment 5
DEAE-Sepharose CL-6B column purification, 0.1mol.L are gone up in the water-soluble back of the polysaccharide (HP) of embodiment 1 to 4 any means gained
-1+ 0.15mol.L
-1The conventional wash-out of NaCl, through dialysis, concentrate, freeze-drying gets HP I 13.5g or 9.6g.Use 0.1mol.L again
-1+ 4.5mol.L
-1The NaCl gradient elution, through dialysis, concentrate, freeze-drying gets HP II4.7g or 3.3g.
Embodiment 6
Tablet
Get Hericium caput-medusae polysaccharide (HP) 200g; medical starch 100g, dextrin 10g mixes; with an amount of 95% alcohol granulation; through the whole grain of pelletizing machine, compressing tablet, every 300mg; oral; each 1-2 sheet, every day twice, other project should meet 2000 editions tablet projects of Pharmacopoeia of People's Republic of China relevant requirements.
Embodiment 7
Capsule
Get Hericium caput-medusae polysaccharide (HP) 200g, medical starch 100g mixes, adorn 1000 of capsules, (every heavy 300mg), oral one day 4-6 grain.
Other project should meet 2000 editions capsule projects of Pharmacopoeia of People's Republic of China relevant requirements.
Embodiment 8
Electuary
Get Hericium caput-medusae polysaccharide (HP) 400g, medical starch 2200g, dextrin 1400g, 95% ethanol is an amount of, and 10 mesh sieves are granulated, and 60 degree are dry, 1000 bags of packing.Oral one time one bag, two bags of every days.
Other project should meet 2000 editions electuary projects of Pharmacopoeia of People's Republic of China relevant requirements.
Embodiment 9
Tablet
Get Hericium caput-medusae polysaccharide (HP I or HP II) 90g, medical starch 160g mixes, with an amount of 95% alcohol granulation, 1000 of compressing tablets, and the heavy 250mg of sheet.Oral once two, every day secondary.
Other project should meet 2000 editions tablet projects of Pharmacopoeia of People's Republic of China relevant requirements.
Embodiment 10
Capsule
Get Hericium caput-medusae polysaccharide (HP I or HP II) 90g, medical starch 160g mixes, encapsulated 1000 (every heavy 250mg).Oral once two, every day secondary.
Other project should meet 2000 editions capsule projects of Pharmacopoeia of People's Republic of China relevant requirements.
Embodiment 11
Electuary
Get Hericium caput-medusae polysaccharide (HP I or HP II) 175g, medical starch 1750g, the smart 1075g that sticks with paste, 95% ethanol is an amount of, 10 mesh sieves are granulated, 60 ℃ of dryings, 1000 bags of packing, oral one time one bag, two bags of every days.
Other project should meet 2000 editions capsule projects of Pharmacopoeia of People's Republic of China relevant requirements.
Claims (9)
1, a kind of Hericium caput-medusae polysaccharide medicinal component, extract by following steps:
Comprise that with the Hericium caput-medusae sporophore mycelium is a raw material, use decocting 1～3 time, each time is 1～3 hour, filters, and merging filtrate concentrates, and adds the 0-3g enzyme, 35～60 ℃ of temperature adjustments, and pH value 5～7, hydrolysis is except that Deproteinization; Add ethanol after the smart filter and carry out alcohol precipitation, ultimate density is 70%, filters collecting precipitation, and is water-soluble, centrifugal slagging-off, getting supernatant liquor alcohol, to be sink to determining alcohol be 70%, collecting precipitation, Hericium caput-medusae polysaccharide HP;
2, a kind of Hericium caput-medusae polysaccharide medicinal component, extract by following steps:
Comprise that with the Hericium caput-medusae sporophore mycelium is a raw material, with 20% alcohol reflux 3 times, each time is 3 hours, united extraction liquid, it is 80% to containing the alcohol amount that concentrating under reduced pressure, concentrated solution add ethanol, alcohol precipitation 2-3 time, left standstill 24 hours, suction filtration, throw out washs in right amount with dehydrated alcohol, drying, be ground into fine powder, get Hericium caput-medusae polysaccharide HP.
3, a kind of effective constituent HP I that extracts from Hericium caput-medusae polysaccharide HP has following structure:
Wherein, A:-
1Fuc
4-; B:-(
1Glc
3-)
2-; C:-(
1Glc
6-)
3-
4, a kind of effective constituent HP II that extracts from Hericium caput-medusae polysaccharide HP has following structure:
Wherein, A:-(
1Glc
3-)
2-; B:-
1Gal
6-.
5, the described Hericium caput-medusae polysaccharide of claim 3 effective ingredient HP I, extract by following steps:
Claim 1 or the water-soluble back of 2 gained polysaccharide HP are gone up DEAE-Sepharose CL-6B column purification, 0.1mol.L
-1+ 0.15mol.L
-1The conventional wash-out of NaCl, through dialysis, concentrate, freeze-drying gets HP I.
6, the described Hericium caput-medusae polysaccharide of claim 4 effective ingredient HP II, extract by following steps:
With claim 1 or 2 gained polysaccharide HP, use 0.1mol.L
-1+ 4.5mol.L
-1The NaCl gradient elution, through dialysis, concentrate, freeze-drying gets HP II.
7, claim 1 or 2 or 3 or 4 described Hericium caput-medusae polysaccharide medicinal components, diseases such as the stomachache that causes in treatment chronic atrophic gastritis, superficial gastritis, peptic gastric ulcer and duodenal bulbar ulcer or other reason, hyperchlorhydria, and have application in the medicine of analgesia, anti-inflammatory action.
8, be used for the treatment of diseases such as chronic atrophic gastritis, superficial gastritis, peptic gastric ulcer and duodenal bulbar ulcer, and have the pharmaceutical composition of analgesia, anti-inflammatory action, wherein contain HP or HP I or HP II or their mixture and the pharmaceutically acceptable carrier for the treatment of significant quantity.
9,, it is characterized in that said medicament is a said formulation on any pharmaceutics according to claim 7,8 described medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031270344A CN1300175C (en) | 2003-05-21 | 2003-05-21 | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031270344A CN1300175C (en) | 2003-05-21 | 2003-05-21 | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1453295A true CN1453295A (en) | 2003-11-05 |
| CN1300175C CN1300175C (en) | 2007-02-14 |
Family
ID=29260351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031270344A Expired - Fee Related CN1300175C (en) | 2003-05-21 | 2003-05-21 | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1300175C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100398564C (en) * | 2005-05-10 | 2008-07-02 | 上海市农业科学院 | Preparation method of semi-bionic extraction of crude polysaccharide from Hericium erinaceus |
| CN101358224B (en) * | 2008-09-04 | 2011-04-27 | 浙江益圣菌物发展有限公司 | Extraction method of hericium erinaceus polysaccharide |
| CN1813819B (en) * | 2005-12-09 | 2011-04-27 | 南京老山药业股份有限公司 | Hedgehog hydnum fruiting body or hyphostroma, culture extract, formulation and preparing method |
| CN102949409A (en) * | 2012-11-08 | 2013-03-06 | 合肥工业大学 | Application of using lachnum exopolysaccharide to prepare medicine for preventing gastric ulcer |
| CN104403021A (en) * | 2014-11-28 | 2015-03-11 | 哈尔滨墨医生物技术有限公司 | Method for extracting high-activity hericium erinaceus polysaccharide |
| CN105142424A (en) * | 2013-04-26 | 2015-12-09 | 李大熙 | Cereal containing hericium erinaceum and method for making same |
| CN110903989A (en) * | 2019-12-21 | 2020-03-24 | 通化兴华药业有限责任公司 | Mar-1 strain of Maria androsaceus, method for artificially culturing Mar-1 mycelium of Maria androsaceus by using Mar-1 strain and pharmaceutical application of Mar-1 strain |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05117303A (en) * | 1991-10-26 | 1993-05-14 | Taku Mizuno | Water-soluble polysaccharides derived from Physcomitrella patens and antitumor agent containing the water-soluble polysaccharides as a main agent |
| JPH09308458A (en) * | 1996-05-20 | 1997-12-02 | Kagome Co Ltd | Treatment for fruiting body of hericium erinoceum |
-
2003
- 2003-05-21 CN CNB031270344A patent/CN1300175C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100398564C (en) * | 2005-05-10 | 2008-07-02 | 上海市农业科学院 | Preparation method of semi-bionic extraction of crude polysaccharide from Hericium erinaceus |
| CN1813819B (en) * | 2005-12-09 | 2011-04-27 | 南京老山药业股份有限公司 | Hedgehog hydnum fruiting body or hyphostroma, culture extract, formulation and preparing method |
| CN101358224B (en) * | 2008-09-04 | 2011-04-27 | 浙江益圣菌物发展有限公司 | Extraction method of hericium erinaceus polysaccharide |
| CN102949409A (en) * | 2012-11-08 | 2013-03-06 | 合肥工业大学 | Application of using lachnum exopolysaccharide to prepare medicine for preventing gastric ulcer |
| CN102949409B (en) * | 2012-11-08 | 2014-10-08 | 合肥工业大学 | Application of using lachnum exopolysaccharide to prepare medicine for preventing gastric ulcer |
| CN105142424A (en) * | 2013-04-26 | 2015-12-09 | 李大熙 | Cereal containing hericium erinaceum and method for making same |
| CN104403021A (en) * | 2014-11-28 | 2015-03-11 | 哈尔滨墨医生物技术有限公司 | Method for extracting high-activity hericium erinaceus polysaccharide |
| CN110903989A (en) * | 2019-12-21 | 2020-03-24 | 通化兴华药业有限责任公司 | Mar-1 strain of Maria androsaceus, method for artificially culturing Mar-1 mycelium of Maria androsaceus by using Mar-1 strain and pharmaceutical application of Mar-1 strain |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1300175C (en) | 2007-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1300175C (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN101066402A (en) | Chineses medicine prepn with several treating functions and its prepn proces and application | |
| CN1183935C (en) | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases | |
| CN1369306A (en) | 'Huajuhong' preparation and its preparing process | |
| CN106822338B (en) | Compound composition for lowering blood sugar and blood lipid, preventing and/or treating diabetes and its complications and use thereof | |
| CN1506090A (en) | Rheum emodi wall extract and medicine composition with the extract as active component | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN103316103B (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
| CN1903227A (en) | Water soluble active component of fermented cordyceps and its application | |
| CN1552425A (en) | A kind of honeysuckle extract and its preparation and use | |
| CN1102066C (en) | Medicine for treating AIDS and tumor and its preparing process | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1236810C (en) | Gastritis treating Chinese medicine | |
| CN1412202A (en) | Ganoderma applanatum polysaccharide, its preparation and medicine composition using said compound as active component | |
| CN1176939C (en) | Pig tooth soap total saponins and its preparation method and its application in the preparation of medicine | |
| CN1626210A (en) | Preparation of 'Sanjin' medication for treating diseases of urinary system and preparation method | |
| CN1546143A (en) | Luyang kidney yang strengthening Chinese traditional medicinal formula and its preparation | |
| CN1785247A (en) | Disintegrant tablets, and its prepn. method | |
| CN1543968A (en) | Medicinal preparation prepared from Cortex Morus alba extract | |
| CN1686281A (en) | Traditional Chinese medicine for treating stomach cancer and its preparation technology | |
| CN101040905A (en) | Medicine made by selfheal for reducing blood sugar | |
| CN1304043C (en) | Longhedan pills and their preparation | |
| CN1803155A (en) | Medicine for curing rhinitis | |
| CN1224397C (en) | Medicine for treating chronic nephritis and production process thereof | |
| CN1523041A (en) | Bulgaria inquinans polysaccharide, method for preparing the same and pharmaceutical composition using the compound as active component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070214 Termination date: 20210521 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |